Production processes should be free from detectable adventitious agents. Traditional tests for adventitious viruses offer opportunities for broad detection of diverse viruses however, these are time consuming tests and have limitations in terms of sensitivity and identification of specific contaminants. Molecular testing technologies such as Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) complement traditional cell-based methods, opening doors for more rapid, sensitive detection of viral contaminants.
Traditional approaches to virus detection– cell-based and in vivo assays - have served the biopharma industry very well over the years, but they have a long turn-around and do not identify specific contaminants. New molecular methods such as broad specificity degenerate PCR, and next generation sequencing (NGS) have been developed not only to replace or supplement traditional test methods but also expand the detection capabilities, thus expediting viral safety testing.
Featured Solution
This white paper examines the current in vivo methods for virus detection and explores alternative testing strategies which can be implemented today.
 |
This white paper examines the current in vivo methods for virus detection and explores alternative testing strategies which can be implemented today.
More Resources
Product Information
Next Generation Sequencing
Our expertise in NGS-based biosafety testing services allows us to provide complete solutions to our clients, from sample preparation and library generation through sequencing and data mining using state of the art computational and bioinformatics platforms, tools and methodologies. These results provide our clients with peace of mind, so they know that their test material is safe for biopharmaceucal production.
Next Generation Sequencing
Our expertise in NGS-based biosafety testing services allows us to provide complete solutions to our clients, from sample preparation and library generation through sequencing and data mining using state of the art computational and bioinformatics platforms, tools and methodologies. These results provide our clients with peace of mind, so they know that their test material is safe for biopharmaceucal production.
